Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1649jxm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN

NEWS EXPRESS	DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:29:06 ON 08 JAN 2004

=> file medline biosis embase caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL

```
                                                    ENTRY     SESSION
FULL ESTIMATED COST                                  0.21        0.21

FILE 'MEDLINE' ENTERED AT 12:29:18 ON 08 JAN 2004

FILE 'BIOSIS' ENTERED AT 12:29:18 ON 08 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 12:29:18 ON 08 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'CAPLUS' ENTERED AT 12:29:18 ON 08 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s slim (s) androgen (s) receptor
L1            0 SLIM (S) ANDROGEN (S) RECEPTOR

=> s slim (p) androgen (p) receptor
L2            0 SLIM (P) ANDROGEN (P) RECEPTOR

=> s slim (p) estrogen (p) receptor
L3            4 SLIM (P) ESTROGEN (P) RECEPTOR

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4             1 DUP REM L3 (3 DUPLICATES REMOVED)

=> d l4 ibib

L4   ANSWER 1 OF 1     MEDLINE on STN                    DUPLICATE 1
ACCESSION NUMBER:    95131407     MEDLINE
DOCUMENT NUMBER:     95131407   PubMed ID: 7830266
TITLE:               Rationally designed analogues of tamoxifen with improved
                     calmodulin antagonism.
AUTHOR:              Hardcastle I R; Rowlands M G; Houghton J; Parr I B; Potter
                     G A; Jarman M; Edwards K J; Laughton C A; Trent J O; Neidle
                     S
CORPORATE SOURCE:    CRC Centre for Cancer Therapeutics, Institute of Cancer
                     Research, Sutton, Surrey, U.K.
SOURCE:              JOURNAL OF MEDICINAL CHEMISTRY, (1995 Jan 20) 38 (2) 241-8.
                     Journal code: 9716531. ISSN: 0022-2623.
PUB. COUNTRY:        United States
DOCUMENT TYPE:       Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:            English
FILE SEGMENT:        Priority Journals
ENTRY MONTH:         199502
ENTRY DATE:          Entered STN: 19950307
                     Last Updated on STN: 19950307
                     Entered Medline: 19950223


=> d l4 total ibib kwic

L4   ANSWER 1 OF 1     MEDLINE on STN                    DUPLICATE 1
ACCESSION NUMBER:    95131407     MEDLINE
DOCUMENT NUMBER:     95131407   PubMed ID: 7830266
TITLE:               Rationally designed analogues of tamoxifen with improved
                     calmodulin antagonism.
AUTHOR:              Hardcastle I R; Rowlands M G; Houghton J; Parr I B; Potter
                     G A; Jarman M; Edwards K J; Laughton C A; Trent J O; Neidle
                     S
CORPORATE SOURCE:    CRC Centre for Cancer Therapeutics, Institute of Cancer
```

Research, Sutton, Surrey, U.K.
SOURCE: JOURNAL OF MEDICINAL CHEMISTRY, (1995 Jan 20) 38 (2) 241-8.
Journal code: 9716531. ISSN: 0022-2623.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199502
ENTRY DATE: Entered STN: 19950307
Last Updated on STN: 19950307
Entered Medline: 19950223

AB . . . rational design of more potent antagonists. Compounds with either three or four methylene units in the basic side chain or **slim** lipophilic 4-substituents were expected to be more potent. All compounds were tested for antagonism of the calmodulin-dependent activity of cAMP phosphodiesterase and for binding affinity to the **estrogen receptor** from rat uteri. Some compounds were assayed for cytotoxicity against MCF-7 breast tumor cells in vitro. Introduction of lipophilic 4-substituents. . . butene) by one or two methylene units resulted in modest gains in calmodulin antagonism (10-13). All the compounds assayed retained **estrogen receptor** binding characteristics. The compound possessing the optimal combination of calmodulin antagonism and **estrogen receptor** binding was 12 ((E)-1-[4-[3-(N-pyrrolidino)propoxy]phenyl]-1-(4-iodophenyl)-2-phenyl-1 - butene) (IC50 = 1.1 microM, RBA = 23). Correlation between calmodulin antagonism and cytotoxicity. . .